DAPASUG-GM-2 Tablet

Description:

• DAPASUG-GM-2 is a triple combination tablet comprising dapagliflozin 10 mg, glimepiride 2 mg, and metformin hydrochloride 1000 mg (extended-release). This formulation is designed for adults with type 2 diabetes mellitus, particularly those with established cardiovascular disease or multiple cardiovascular risk factors, to improve glycemic control and reduce the risk of hospitalization for heart failure.
• As a premier dapagliflozin 10mg tablets manufacturer, alongside trusted glimepiride tablets 2 mg manufacturers, our commitment to quality shines through every batch. We also serve as key glimepiride tablets 2 mg suppliers and exporters, making this powerful combo accessible worldwide with reliability and speed.

Key Features:

• Dapagliflozin promotes urinary glucose excretion, aiding in blood sugar reduction and weight management.
• Glimepiride stimulates insulin secretion from pancreatic beta cells, enhancing glucose utilization.
• Metformin decreases hepatic glucose production and improves insulin sensitivity.
• The extended-release formulation of metformin ensures prolonged glycemic control and improved gastrointestinal tolerability.
• Once-daily dosing regimen simplifies therapy and enhances patient adherence.

Usage Guidelines:

• Administer one tablet orally once daily with meals to minimize gastrointestinal side effects.
• Suitable for adults with type 2 diabetes mellitus requiring comprehensive glycemic management.
• Regular monitoring of renal function and blood glucose levels is recommended to ensure efficacy and safety.

Safety Profile:

• Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and urinary tract infections.
• Not recommended for patients with type 1 diabetes or diabetic ketoacidosis.
• Caution is advised in patients with renal or hepatic impairment, and in those at risk for lactic acidosis.

Uses / Indications: Patients with T2D with eCVD or multiple CV risk factors, to reduce the risk of hospitalization for heart failure